Nasdaq:US$13.47 (-0.42) | HKEX:HK$21.60 (-0.85) | AIM:£2.02 (-0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)